Receptor status of breast cancer diagnosed during pregnancy: A literature review

Carsten F. J. Bakhuis, Britt B. M. Suelmann, Carmen van Dooijeweert, Sabine Linn, Elsken van der Wall, Paul J. van Diest

Research output: Contribution to journalReview articlepeer-review

Abstract

The definition of PABC is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with breast cancer diagnosed within six months to five years after delivery, and sometimes even longer. The longer away from the delivery date breast cancer is diagnosed, the less clear this association with pregnancy may become. Therefore, breast cancer diagnosed during pregnancy (BCdP) may not necessarily be the same disease entity as PABC. This review aims to provide an overview of BCdP receptor status, as this has not been assessed before. BCdP tumors were predominantly ER negative (56.6 %), PR negative (57.2 %) or both ER and PR negative (47.9 %). Moreover, HER2-overexpression was seen in 33.2 % of BCdP patients and 27.6 % had triple negative disease. This predominantly ER and PR negative profile with more often HER2 overexpression is aggressive and distinct from non-pregnant similar-aged patients, warranting future comparative research.
Original languageEnglish
Article number103494
JournalCritical Reviews in Oncology Hematology
Volume168
DOIs
Publication statusPublished - Dec 2021

Keywords

  • Breast cancer
  • Estrogen receptor
  • HER2
  • Pregnancy
  • Progesterone receptor

Fingerprint

Dive into the research topics of 'Receptor status of breast cancer diagnosed during pregnancy: A literature review'. Together they form a unique fingerprint.

Cite this